Worth reading
37Immaterial
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
28
% (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSNet Sales573,033¥ millionYear on year +5.0%Progress 23.1%
Operating profit39,659¥ millionYear on year +28.0%Progress 18.8%
Ordinary income50,344¥ millionYear on year +31.6%Progress 19.5%
Net income attributable to owners of the parent27,078¥ millionYear on year +11.3%Progress 17.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥33.46
Financial position at period-end
Total assets3,408,011¥ million
of which net assets 1,625,813 ¥ millionEquity ratio 38.7%vs. prior year-end +1.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+74,231
Investment-25,605
Financials-58,497
Net change-9,871
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥124,053 million
Segment revenue
Alcoholic beverages248,14343.8%-0.3%
Beverages136,27724.1%+7.2%
Pharmaceuticals118,38820.9%+13.1%
Health Science63,75711.3%+4.8%
Segment profit
Alcoholic beverages30,28845.3%+12.3%
Beverages13,43620.1%+15.0%
Pharmaceuticals17,15625.6%+79.5%
Health Science6,0279.0%+88.2%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥2,480,000 million (YoY +1.9%)
Operating profit¥211,000 million (YoY +0.6%)
Ordinary income¥258,000 million (YoY +8.5%)
Net income¥156,000 million (YoY +5.7%)
Annual Dividend Forecast¥74 → ¥76（+2.7%）
Factors Behind Changes in Business Performance
The financial results summary does not explain the reasons for changes in operating performance, stating that these details will be provided in the financial results presentation materials.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 Not disclosed
Changes in the scope of consolidationNew Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None
Impairment loss¥4,891 million
Depreciation and amortization¥27,253 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and securities analysts
Issued Shares at Period-End816,000,000
Treasury Shares at Period-End9,169,410
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥573,033 million (YoY +5.0%) |
| Operating profit | ¥39,659 million (YoY +28.0%) |
| Ordinary income | ¥50,344 million (YoY +31.6%) |
| Profit attributable to owners of the parent | ¥27,078 million (YoY +11.3%) |
| Net income per share | ¥33.46 |
| Equity ratio | End of the current fiscal period 38.7% / End of previous period 36.8% |
| Total assets | ¥3,408,011 million |
| Net assets | ¥1,625,813 million |
| Cash flows from operating activities | ¥74,231 million |
| Cash flows from investing activities | ¥-25,605 million |
| Cash flows from financing activities | ¥-58,497 million |
| Cash and cash equivalents at end of period | ¥124,053 million |
| Full-year earnings forecast | Net Sales ¥2,480,000 million (YoY +1.9%) / Operating profit ¥211,000 million (YoY +0.6%) / Ordinary income ¥258,000 million (YoY +8.5%) / Net income ¥156,000 million (YoY +5.7%) |
| Annual Dividend Forecast | ¥74 → ¥76（+2.7%） |
| Segment revenue | Alcoholic beverages ¥248,143 million (YoY -0.3%) / Beverages ¥136,277 million (YoY +7.2%) / Pharmaceuticals ¥118,388 million (YoY +13.1%) / Health Science ¥63,757 million (YoY +4.8%) |
| Segment profit | Alcoholic beverages ¥30,288 million (YoY +12.3%) / Beverages ¥13,436 million (YoY +15.0%) / Pharmaceuticals ¥17,156 million (YoY +79.5%) / Health Science ¥6,027 million (YoY +88.2%) |
| Depreciation and amortization | ¥27,253 million |
| Impairment loss | ¥4,891 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Number of companies 0 / Company name None / Excluded Number of companies 0 / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and securities analysts |
| Issued Shares at Period-End | 816,000,000 |
| Treasury Shares at Period-End | 9,169,410 |
| Factors Behind Changes in Business Performance | The financial results summary does not explain the reasons for changes in operating performance, stating that these details will be provided in the financial results presentation materials. |
Items this document does not state (8)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogBreakdown of extraordinary income (loss)Material subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The financial results summary does not explain the reasons for changes in operating performance, stating that these details will be provided in the financial results presentation materials.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.